메인메뉴 바로가기

All Menu

Hanmi Fine Chemical.Co.,Ltd.

글로벌메뉴

메인메뉴


HomeR&DResearch

R&D

Research

Research & Pipeline Products
Date Content
2016.01
R&D completed on Rosuvastatin, Ezetimibe, Solifenacin and Febuxostat
2015.01
CMO multinational collaborative research in progress
2015.01
Completed the R&D of Tenofovir Disoproxil
2015.01
Completed the R&D of Silodosin
2015.01
Esomeprazole Strontium Tetrahydrate US Register
2015.01
Irbesartan, Raloxifene MF 1-st source register and complete entry
2014.01
Completed the R&D of Celecoxib, Duloxetine, HM61713
2013.01
Completed the R&D of Telmisartan
2012.01
Completed the R&D of Moxifloxacin HCl
2012.01
Completed the R&D of Candesartan Cilexetil
2011.01
Completed the R&D of Bepotastine Besilate
2011.01
Completed the R&D of Imatinib Mesilate
2011.01
Completed the development of Esomeprazole-free Base (new, modified drug): Medication for reflux esophagitis and gastric ulcer
2010.01
Completed the development of Atorvastatin Calcium Trihydtare (generic): Medication for hyperlipidemia
2010.01
Completed the development of Adefovir Dipivoxil (generic): Medication for hepatitis
2010.01
Completed the development of Levocetirizine Dihydrochloride (generic): Anti-allergy medication
2010.01
Completed the development of Voglibose (generic): Medication for diabetes
2010.01
Completed the development of Valaciclovir Hydrochloride: Medication for herpes zoster
2009.01
Completed the R&D and commenced mass production of Orlistat (Lipidown), anti-obesity agents, Pioglitazone HCl
2009.01
Completed the R&D of Pregabalin
2009.01
Completed the development of Atorvastatin Strontium Pentahydrate (new, modified drug): medication for hyperlipidemia
2009.01
Launched and mass produce Orlistat (Lipidown), anti-obesity agents
2008.01
Developed a new synthetic method for Montelukast, the anti-asthma agent
2008.01
Developed a new synthesis method for Montelukast (anti-asthma agent)
2007.06
Conducted R&D projects on more than 20 new products
2007.04
Established the Research Planning Team; established future-oriented mid- and long-term strategies
2007.01
Completed the development of Clopidogrel Napadisilate Monohydrate (new, modified drug): antithrombotic agent
2007.01
Completed the development of Esomeprazole Strontium Tetrahydrate (new, modified drug): medication for reflux esophagitis and gastric ulcer
2007.01
Developed a new synthetic method for Capecitabine, the anti-cancer drug
2006.11
Established a pharmaceutical analysis lab with the latest equipment such as LC-Mass, UPLC, HPLC, etc.
2006.09
Established the Analytical Research Team and conducted DMF from the research stage
2006.08
Completed R&D of Losartan K (medication for hypertension)
2006.05
Completed R&D of Donepezil HCI (medication for dementia)
2006.04
Completed R&D of Pioglitazone HCl (medication for diabetes)
2006.01
Completed R&D of Rabeprazole (medication for gastric ulcer)
2006.01
Completed R&D of Gemcitabine HCl (generic): antibiotics
2006.01
Developed synthetic methods for Pioglitazone hydrochloride, Donepezil HCl, Losartan K
2005.10
Cefpodoxime Proxetil (oral cepha-based antiobiotics)
2005.08
Completed R&D of Rebamipide (medication for gastric ulcer)
2005.03
completed research on Cefazolin and Cedinir (cepha-based antibiotics)
2005.01
Marketed Amodipine Camsylate (medication for hypertension)
2005.01
Developed synthetic methods for Amlodipine camsylate, Cefdinir
2004.10
Conducted the project for “Manufacturing of Non-toxic and High-efficiency Active Pharmaceutical Ingredients Using Supercritical Processes (Energy-Resource Technology Development Project)”
2004.08
Ceftizoxime (4th generation injectable cepha-based antibiotics)
2004.06
Cefepime (oral cepha-based antibiotics)
2004.02
Developed Cefcapene Pivoxil (oral cepha-based antibiotics)
2004.01
Developed synthetic methods for Ceftrizoxime, the 4th generation injection cephalosporin antibiotic.
2003.08
Improved the manufacturing process for Itraconazole (anti-fungal agent)
2003.05
Produced the trial version of Sertralin (anti-depression medication)
2003.01
Developed synthetic methods for Sertralin and Itraconazole.
2002.09
Developed synthesis methods for Lansoprazole (medication for gastric ulcer)
2002.05
Developed synthesis methods for Simvastatin (medication for hyperlipidemia)
2002.01
Developed synthetic methods for Simvastatin and Lansoprazole.
2001.09
Acquired US patents for the methods of manufacturing Ceftazidime and Cefixime
2001.07
Improved the manufacturing process for Ceftiopher (cepha-based antibiotics for animals)
2001.03
Cefpodoxime Proxetil (oral antibiotics)
2001.01
Developed a synthetic process for Cefpodoxime proxetil, 3rd generation oral cephalosporin antibiotics
2000.08
Acquired US patents for intermediates (i.e., Cefixime and Ceftazidime)
2000.05
Developed Aceclofenac (medication for arthritis)
2000.02
Developed a new synthesis method for Ceftazidime (developed a new material as the key intermediate)
2000.01
Developed a new synthesis method for Cefixime and applied for patent
1999.07
Developed a synthesis method for Cefuroxime Axetil and produced trial products
1999.03
Developed a synthesis method for Cefuroxime Sodium
1999.01
Developed a synthetic process for Clarithromycin, the 3rd generation antibiotic
1998.02
Developed synthesis methods for AMCA and Cefmetazole
1997.07
Developed a synthesis method for Cefixime
1997.01
Developed a synthetic method for Cefixime, the 3rd generation oral antibiotic
1996.04
Developed a synthesis method for Cefoperazone
1995.04
Developed a synthesis method for Ceftazidime
1995.01
Developed a synthetic method for Ceftazidime pentahydrate, the 3rd generation injectable antibiotic
1994.03
Developed a synthesis method for Cefotiam
1994.01
Developed a synthetic method for Cefotiam hydrochloride, the 2nd generation injectable cephalosporin
1989.03
Transferred technology to Swiss Roche (Ceftriaxone)
1989.01
Transferred synthetic technology of 3rd generation cephalosporin, Ceftriaxone, to Hoffman-La Roche
1987.09
Developed a synthesis method for Ceftriaxone
1987.01
Developed a synthetic process for Ceftriaxone, the 3rd generation
1986.04
Publicly announced the products domestically developed to substitute imports
1985.06
Designated as a new domestic technology and product for protection
1984.05
Developed a synthesis method for Cefotaxime (first to localize the production in Korea)
1984.01
Developed a new synthetic method for Cefotaxime, the 3rd generation cephalosporin antibiotic
TOP

Add.
59, Gyeongje-ro, Siheung-si, Gyeonggi-do, Korea
Tel.
+82-031-499-2541
Fax.
+82-031-499-2540

COPYRIGHT(C) 2013 BY HANMI FINE CHEMICAL CORPORATION. ALL RIGHT RESERVED.